The Liu Laboratory
The Liu laboratory applies biostatistics to several areas of research, including: basic cancer research and clinical trials of cancer immunotherapy; infectious diseases; behavioral and educational intervention research; and research on health care outcomes.
Xiangfan Yin, M.S.
The Biostatistics Unit supervised by Liu provides in-house biostatistics expertise to accommodate continuing growth in translational and pre-clinical cancer research. This Unit provides statistical support to biological laboratories at Wistar and its tasks include, but not limited to, large data management, experiment design, statistical data analysis, data presentation for manuscripts and grant proposal development. Liu has extensive experience working with basic and clinical investigators on statistical issues. Her strong statistical and biomedical backgrounds have enabled her to provide exceptionally high levels of scientific input to different projects. As a result, her effort has contributed to many published papers and funded grant proposals for clinical and basic science investigators. Within a short time after she joined The Wistar Institute, she engaged in a plethora of collaborative projects with Wistar Cancer Center members and obtained joint NIH funding with inside and outside Wistar investigators, including two P01 Program Project grants on novel molecular therapies of prostate cancer and melanoma targeted therapies. There is significant institutional support for collaborative efforts between the Biostatistics Unit and the investigators at Wistar.
Liu, Q., Yin, X., Languino, L.R., Altieri, D.C. "Evaluation of drug combination effect using a Bliss independence dose-response surface model." Statistics in Biopharmaceutical Research 2018.10:2, 112-122, DOI: 10.1080/19466315.2018.1437071.
Reyes-Uribe, P., Adrianzen-Ruesta, M.P., Deng, Z., Echevarria-Vargas, I., Mender, I., Saheb, S., Liu, Q., Altieri, D.C., Murphy, M.E., Shay, J.W., et al. "Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma." Oncogene. 2018 Apr 26. doi: 10.1038/s41388-018-0247-7. [Epub ahead of print]
Echevarría-Vargas, I.M., Reyes-Uribe, P.I., Guterres, A.N., Yin, X., Kossenkov, A.V., Liu, Q., Zhang, G., Krepler, C., Cheng, C., Wei, Z., et al. "Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma." EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.
Zhang, G., Wu, L.W., Mender, I., Barzily-Rokni, M., Hammond, M.R., Ope, O., Cheng, C., Vasilopoulos, T., Randell, S., Sadek, N., et al. "Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma." Clin Cancer Res. 2018 Mar 21. pii: clincanres.2773.2017. doi: 10.1158/1078-0432.CCR-17-2773. [Epub ahead of print]
Lu, H., Bowler, N. Harshyne, L.A., Craig Hooper, D., Krishn, S.R., Kurtoglu, S., Fedele, C., Liu, Q., Tang, H.Y., Kossenkov, A.V., et al. "Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer." Matrix Biol. 2018 Mar 9. pii: S0945-053X(18)30081-7. doi: 10.1016/j.matbio.2018.03.009. [Epub ahead of print]
Paul M. Lieberman, Ph.D.
Hilary Koprowski, M.D., Endowed Professor and Program Leader, Gene Expression & Regulation Program, The Wistar Institute Cancer Center
Director, Center for Chemical Biology & Translational Medicine
Luis J. Montaner, D.V.M., D.Phil.
Vice President, Scientific Operations
Associate Director for Shared Resources, The Wistar Institute Cancer Center
Herbert Kean, M.D., Family Endowed Chair Professor; Director, HIV-1 Immunopathogenesis Laboratory and Leader, HIV Research Program, Vaccine & Immunotherapy Center;
Immunology, Microenvironment & Metastasis Program, The Wistar Institute Cancer Center